Dear Sir/Madam,

I write to strongly support the USPTO's May 9, 2018 proposal entitled "Changes to the Claims Construction Standard for Interpreting Claims in Trial Proceedings Before the PTAB" (83 Fed. Reg. 21221), and urge you to adopt this rule as soon as possible.

I call upon you to take this action to crack down on abuses that undermine the ability of innovative biotechnology companies to rely on their patents to raise and invest the hundreds of millions of dollars needed to develop and bring to market the next generation of cures – as well as innovations in sustainable agriculture, renewable energy, and a variety of other biobased products.

Replacing the broadest reasonable interpretation standard for construing unexpired patents with the standard used in Federal district courts and the International Trade Commission is an essential step towards restoring America's patent system to the gold standard status that it once held. As it currently stands, competing claim construction standards have encouraged duplicative patent reviews that undermine the carefully balanced, Congressionally-mandated system that has successfully spurred both innovation and generic drug entry for decades.

It essential to the basic concept of fairness that you adopt this rule to harmonize the competing patent adjudication systems.

Regards, Joe Hansen 1050 N Taylor St Arlington, VA 22201